EpLCART: A phase II open-label, multi-centre study of minimal residual disease-directed consolidation with epcoritamab or epcoritamab-lenalidomide-rituximab post anti-CD19 CAR T-cell therapy for large B-cell lymphoma

  • Inam, Shafqat (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date13/06/24 → 13/06/26

Keywords

  • Clinical trial
  • 22/012